Abstract: In alternative embodiments, provided are biosensing bioreactors that detect normal, pre-cancer and cancer stem cells. In alternative embodiments, provided are bioreactors for primary human hematopoietic stem and progenitor cell culture, manipulation and maintenance, which can comprise micro-peristaltic pumps to recapitulate blood flow. In alternative embodiments, provided are products of manufacture in the form of a bioreactor, or a nanobioreactor, or a customized cell culture bag with a defined three dimensional (3D) stromal microenvironment, and kits comprising them, and methods for making and using them. In alternative embodiments, the products of manufacture as provided herein, including the bioreactor, nanobioreactor, bag, customized cell culture bag and kits as provided herein, are used to and are capable of culturing, maintaining or supporting the culture of, and/or differentiating hematopoietic stem cells, including human hematopoietic stem cells, isolated from bone marrow or blood donors.

Abstract: In alternative embodiments, provided are methods for treating and ameliorating a cancer, or recurrence of a cancer such as acute myeloid leukemia (AML) comprising administration to an individual in need thereof a pharmaceutical composition comprising 17S-FD-895 (or rebecsinib) and second drug such as an ATP-competitive protein tyrosine kinase inhibitor such as dasatinib. In alternative embodiments, provided are methods for the in vivo inhibition of myeloproliferative neoplasm (MPN) or AML stem cell propagation comprising administration to an individual in need thereof a pharmaceutical composition comprising 17S-FD-895 and second drug. In alternative embodiments, provided are methods for the in vivo inhibition pre-leukemia stem cell (pre-LSC) transformation into leukemia stem cells (LSCs) comprising administration to an individual in need thereof a pharmaceutical composition comprising 17S-FD-895 and second drug.